Pharming Group (PHAR)
(Delayed Data from NSDQ)
$10.96 USD
-0.15 (-1.35%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.08 +0.12 (1.09%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PHAR 10.96 -0.15(-1.35%)
Will PHAR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PHAR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAR
New Strong Buy Stocks for August 1st
Best Momentum Stocks to Buy for July 25th
PHAR: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 25th
Best Momentum Stocks to Buy for July 17th
New Strong Buy Stocks for July 17th
Other News for PHAR
Pharming (PHAR) Stock Target Raised by Oppenheimer Following Q2 Results
Pharming price target raised by $1 at Oppenheimer, here's why
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Pharming Group N.V. 2025 Q2 - Results - Earnings Call Presentation
Pharming Group N.V. GAAP EPS of $0.006, revenue of $93.2M